🇺🇸 FDA
Pipeline program

VX15/2503

VX15/2503-N-131

Phase 2 small_molecule completed

Quick answer

VX15/2503 for Huntington's Disease is a Phase 2 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
VACCINEX, INC.
Indication
Huntington's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials